PARKHOSPS
Park Medi World share price & financials
- Price
- ₹273.95
- Market cap
- ₹12.6k Cr
- Sector
- Healthcare
- Calls analysed
- 3
Park Medi World Limited Q1 FY27
What went well
- Revenue from operations of ₹476 crores, up 19% year-on-year, driven by steady patient volume and ramp-up at newer hospitals.
- Operating EBITDA stood at ₹126 crores, a 20% year-on-year growth, with a margin of 26.5% (improvement from 26.3% in Q1 FY26).
- PAT came in at ₹89 crores, a 35% year-on-year growth, with a PAT margin of 18.6% (expansion of 220 basis points YoY).
What to watch
- Network occupancy for Q1 FY27 stood at 56%, down from 68% in Q1 FY26, reflecting the step-up in capacity over the past 12 months.
- Fuller impact of CGHS rate revision (7-7.5% benefit) will be visible from Q2, as Q1 benefit was partially offset by CAPEX spending for upgrades.
What Park Medi World Limited does
Park Medi World operates a cluster-based network of multi-specialty and super-specialty hospitals across North India, delivering inpatient (IPD) and outpatient (OPD) care across more than 30 clinical specialities. The group has grown over two decades through a mix of greenfield hospital construction and acquisitions of existing hospitals, which are integrated and largely operated under the Park Hospital brand. Revenue comes from patient treatment and diagnostic services delivered through its owned and operated hospital network, serving patients under both government and private insurance payor channels.
Segments
- Hospital Services
- Hospitals operated
- 16
- Total bed capacity
- 3,960 beds (including 1,040 ICU beds)
- Market position
- Largest private hospital chain in Haryana & Tricity; second-largest in North India
- Geographic footprint
- 14 cities across 5 states
- Doctors
- 968
- Nurses
- 2215
Guidance record · Q1 FY27
what the last two calls moved 27 tracked 0 delivered 2 missed 25 open- Gross Debt missed said Q3 FY26 Promised: So by end of Feb, we will be completely debt-free company. Q1 FY27: Term debt (excluding lease liability) reduced to INR 25.6 crores as of June 30, 2026, from INR 28.2 crores in the previous quarter. The original promise remains missed.
- Bed Strength revised up said Q3 FY26 Promised: In FY '28, we will be aspiring for 850 beds... which should take us to roughly 5,260 beds. Q1 FY27: The target for FY28 has been revised up again to 5,740 beds, from the previous revision of 5,460 beds.
- EBITDA Margin on track said Q3 FY26 Promised: EBITDA is expected to remain in 26%-27% range going forward for mid to long term. Q1 FY27: Q1 FY27 EBITDA margin was 26.5%, falling within the guided range. Management reiterated a blended EBITDA margin guidance of 26.7%-27% for FY27.
All 27 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 19.3%, net profit up 34.8% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 348 | 354 | 399 | 410 | 410 +18% | 460 +30% | 476 +19% |
| EBITDA | 83 | 88 | 105 | 113 | 99 +19% | 127 +44% | 126 +20% |
| Net profit | 46 | 52 | 66 | 79 | 53 +15% | 77 +48% | 89 +35% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +86.3% YTD
YTD: ₹149.9 on 1 Jan 2026 → ₹279.3. High ₹299.3 (30 Jun 2026), low ₹143.92 (12 Jan 2026).
How the price took the results
close before → close after
- Q1 FY27
- −1.6%
- 4 Aug
- Q4 FY26
- +0.6%
- 13 May
- Q3 FY26
- −3.6%
- 29 Jan
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
| Year ending | FY26 |
|---|---|
| Revenue | ₹1.7k Cr |
| Operating profit | ₹444 Cr |
| Operating margin | 26.4% |
| Interest | ₹59 Cr |
| Depreciation | ₹63 Cr |
| Net profit | ₹275 Cr |
| Net margin | 16.4% |
| Cash from operations | ₹329 Cr |
| Free cash flow | ₹209 Cr |
| ROCE | 19.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹19 Cr | ₹77 Cr | ₹77 Cr | ₹77 Cr | ₹77 Cr | ₹86 Cr |
| Reserves | ₹256 Cr | ₹380 Cr | ₹610 Cr | ₹806 Cr | ₹1.1k Cr | ₹1.9k Cr |
| Borrowings | ₹292 Cr | ₹517 Cr | ₹576 Cr | ₹687 Cr | ₹734 Cr | ₹364 Cr |
| Other liabilities | ₹249 Cr | ₹319 Cr | ₹331 Cr | ₹343 Cr | ₹386 Cr | ₹427 Cr |
| Total liabilities | ₹816 Cr | ₹1.3k Cr | ₹1.6k Cr | ₹1.9k Cr | ₹2.3k Cr | ₹2.8k Cr |
| Fixed assets | ₹365 Cr | ₹458 Cr | ₹536 Cr | ₹837 Cr | ₹933 Cr | ₹1.3k Cr |
| Capital work in progress | ₹7 Cr | ₹29 Cr | ₹5 Cr | ₹32 Cr | ₹54 Cr | ₹123 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹443 Cr | ₹806 Cr | ₹1.1k Cr | ₹1.0k Cr | ₹1.3k Cr | ₹1.4k Cr |
| Total assets | ₹816 Cr | ₹1.3k Cr | ₹1.6k Cr | ₹1.9k Cr | ₹2.3k Cr | ₹2.8k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Dec 2025, FIIs trimmed −0.46 pp while DIIs added +0.37 pp. The shareholder count shrank 54% to 52,428.
- Promoters
- 82.9%
- FIIs
- 0.8%
- DIIs
- 8.9%
- Public
- 7.3%
Since Dec 2025
- FIIs −0.46 pp
- DIIs +0.37 pp
- Public +0.27 pp
How it drifted, 3 quarters
Ownership split by quarter, oldest first. Dec '25: Promoters 82.9%, FIIs 1.3%, DIIs 8.6%, Government 0.2%, Public 7.1%.Mar '26: Promoters 82.9%, FIIs 0.9%, DIIs 8.9%, Government 0.3%, Public 7.0%.Jun '26: Promoters 82.9%, FIIs 0.8%, DIIs 8.9%, Public 7.3%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Park Medi World Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Ajit Gupta | 74.59% | unchanged |
| Ankit Gupta | 8.31% | unchanged |
| Kotak Contra Fund Mutual fund | 5.11% | unchanged |
| Carnelian Bharat Amritkaal Fund AIF | 1.04% | unchanged |
| Aditya Gupta | 0.00% | unchanged |
| Rajni Gupta | 0.00% | unchanged |
| Madhu Gupta | 0.00% | unchanged |
| Usha Aggarwal | 0.00% | unchanged |
| Abhishek Aggarwal | 0.00% | unchanged |
| Shri Amar Charitable Trust | 0.00% | unchanged |
| Healplus Labs Private Limited | 0.00% | unchanged |
| Healcare Health Infra Private Limited | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- 26.7% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
All earnings calls (3)
Read the Q1 FY27 call →Learn to analyse Park Medi World Limited
Guides on how to read this kind of business and the numbers that matter.